Nature, Published online: 26 June 2026; doi:10.1038/d41586-026-01976-w A handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high cholesterol to a rare muscular disorder.
CRISPR technology has matured, allowing for more targeted and sophisticated interventions, specifically in epigenetics to address a wider range of diseases.
This represents a significant advancement in therapeutic approaches, moving beyond genetic editing to influence gene expression without altering the underlying DNA sequence, opening new avenues for treating complex conditions.
The scope of treatable diseases using genetic technologies expands significantly, encompassing conditions previously thought intractable due to their epigenetic origins.
- · Biotech companies specializing in epigenetic therapies
- · Patients with high cholesterol and rare muscular disorders
- · Venture capital firms backing early-stage biopharma
- · Pharmaceutical companies reliant on conventional drug discovery
- · Researchers focused solely on germline gene editing
Epigenetic editing becomes a new frontier in precision medicine, leading to novel drug development pipelines.
Increased investment and competition in the synthetic biology sector, driving down costs and improving accessibility of these advanced therapies.
Ethical and regulatory frameworks will need to evolve rapidly to address the implications of manipulating gene expression at scale.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at Nature — Latest Research